Currently, a dose-escalation Phase I study of MK-2206 combined with the EGFR-TKI gefitinib is being conducted in patients with NSCLC, particularly enriched with patients harboring EGFR mutations [113]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.